# Japanese AI Camera System Redefines Throat Exams by Diagnosing Flu in Ten Seconds Without Nasal Swabs

> Tokyo startup Iris, led by Sho Okuyama, has developed Nodoca, an AI-equipped camera system that analyzes pharyngeal images to deliver precise influenza diagnoses in just ten seconds.

**Type:** article · **Category:** Technology · **Published:** 2026-08-05 · **Source:** TrendKia
**Canonical:** https://trendkia.com/en/technology/japan-men-ai-kaimara-takanika-ka-kamala-naka-men-bina-svaiba-dale-10-seknda-men-hogi-phlu-ki-satika-jancha-13937 · **Language:** English
**Tags:** Japan, Iris, Nodoca, Sho Okuyama, HealthTech, Artificial Intelligence, Influenza, Covid-19

A throat examination has long remained one of the most static and unchanged elements of a routine physical, standing alongside temperature checks and listening to a heartbeat. Yet the patterns formed on the mucous membranes and blood vessels of the pharynx vary distinctly according to the infecting pathogen, concealing a wealth of diagnostic intelligence. Tokyo-based medical technology startup Iris, founded by former emergency physician Sho Okuyama, is now unlocking this hidden information by leveraging specialized hardware and artificial intelligence.

## Eliminating Swab Discomfort with Pharyngeal AI Imaging
Traditional diagnostic methods for respiratory infections like influenza rely heavily on inserting a swab deep into the nasal cavity to collect a specimen. This process is notoriously uncomfortable for patients and often demands waiting until symptoms fully manifest to yield reliable results. The system created by Iris, known as Nodoca, completely bypasses this painful routine. Nodoca employs a compact device equipped with a specialized camera to capture high-definition images of the pharynx. By combining these pharyngeal photographs with clinical data gathered during the patient interview, the AI system evaluates the presence of influenza in just over 10 seconds. Furthermore, because it detects subtle mucosal changes, Nodoca can be effectively deployed at a much earlier stage following the onset of symptoms.

## Regulatory Milestone and Integration Across Hospitals
Nodoca achieved a historic regulatory breakthrough in 2022 when it became Japan's very first AI-driven medical device to receive approval as a "new medical device" while simultaneously gaining reimbursement coverage under the national health insurance system. This regulatory support catalyzed rapid clinical adoption. To date, more than 2,000 medical institutions across Japan have integrated Nodoca into their daily diagnostic procedures. Expanding its diagnostic footprint further, regulatory authorities granted additional approval in October 2025 for a new function capable of evaluating Covid-19 infection patterns, reinforcing the device's role as a multi-pathogen screening tool.

## Rural Medical Roots and Hardware Innovation
The conceptual foundation of Nodoca originated from Okuyama's firsthand experiences working as a doctor in isolated communities. Early in his career, Okuyama practiced medicine on remote Japanese islands populated by only a few hundred residents. Lacking advanced diagnostic machinery, he had to rely almost entirely on a basic stethoscope alongside his own visual and auditory observations. This experience shaped his approach to medical AI. While most health-tech developers focus exclusively on diagnostic algorithms, Okuyama recognized that data acquisition hardware was the primary differentiator. He noted, **"When people hear medical AI, they think of diagnosis, but the real differentiating factor lies in sensing and acquiring data."** By developing proprietary camera hardware tailored specifically for pharyngeal imaging, Iris ventured into an unmapped area of clinical sensing.

## Overcoming Data Scarcity to Build a Market Barrier
When Iris was launched in 2017, there were no existing datasets of throat images available to train artificial intelligence models. To bridge this gap, Okuyama provided specialized cameras to approximately 100 medical centers, collecting patient-consented images over a three-year span. By navigating three major uncertainties—custom hardware engineering, dataset accumulation, and demonstrating clinical AI accuracy—Iris paved the way for commercialization. Once Nodoca entered active clinical use, a powerful network effect took hold. Anonymized data continuously feeds into the platform, expanding the training library from hundreds of thousands of pre-launch images to several million today. This vast repository creates a formidable competitive barrier, preventing latecomers from easily entering the market.

## Future Horizons: Chronic Disease Screening and Global Expansion
The clinical possibilities of Nodoca extend well beyond acute viral infections. Because mucosal vascular patterns reflect systemic health indicators, Iris is currently conducting research to train its AI algorithms to detect chronic lifestyle-related conditions, including hypertension and diabetes, directly from throat images. Okuyama envisions that within ten years, a single photograph of the throat will enable a comprehensive battery of health screenings. Since the computational cost of AI inference is negligible, expanding the range of tests adds virtually no marginal cost. To support this systemic shift, Okuyama is actively advocating for regulatory reforms and engaging with government officials to streamline AI integration across primary care and specialized medicine. Additionally, because human mucous membrane characteristics remain consistent globally, the algorithms trained in Japan can be applied internationally, with preparations already underway for US clinical trials.

## What this means for you
**For Patients:** Painful nasal swab tests for flu can be replaced with a painless 10-second camera scan of the throat at clinics using this technology.

**For Future Healthcare:** In the coming decade, a simple photo of the throat could screen for chronic lifestyle conditions like diabetes and hypertension at almost no added cost.

## Questions & Answers

### 1. What is Nodoca and how does it work?
Nodoca is an AI-powered medical camera system developed by Japanese startup Iris that analyzes throat images and patient data to diagnose influenza in just over 10 seconds.

### 2. Does Nodoca require a nasal swab test?
No, Nodoca eliminates the need for uncomfortable nasal swab collection by relying entirely on optical images of the throat taken with a specialized camera.

### 3. Is Nodoca approved for use in healthcare facilities?
Yes, it was approved in Japan in 2022 under national health insurance and is used in over 2,000 medical institutions, with additional approval for Covid-19 granted in October 2025.

### 4. What other diseases could Nodoca detect in the future?
Iris is researching ways to train Nodoca's AI to identify signs of chronic lifestyle diseases, such as diabetes and hypertension, through throat mucosal patterns.

## Inspiration & Lessons
**Focus on Sensing Hardware:** True differentiation comes from solving data acquisition and building specialized hardware, not just developing software algorithms.

**Overcoming Data Scarcity:** When no training data existed, the founder partnered with 100 medical centers over 3 years to build a proprietary dataset from scratch.

**Learning from Ground Reality:** Practicing medicine in remote areas with minimal tools inspired a vision to simplify diagnostics for everyone.

---
_TrendKia — Har trend, sabse pehle.. Machine-readable view; canonical HTML at the URL above._